Chaveli López B, Gavaldá Esteve C, Sarrión Pérez MG. Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent. 2011;3(1):e31-42.






1. López-Galindo MP, Bagán JV, Jiménez-Soriano Y, Alpiste F, Camps C. Clinical evaluation of dental and periodontal status in a group of oncological patients before chemotherapy. Med Oral Patol Oral Cir Bucal. 2006;11:E17-21.

2. Caribé-Gomes F, Chimenos-Küstner E, López-López J, Finestres-Zubeldia F, Guix-Melcior B. Dental management of the complications of radio and chemotherapy in oral cancer. Med Oral. 2003;8:178-87.

3. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Cancer. 2004;100:2261-8.

4. Hueso L, Sanmartín O, Nagore E, Botella-Estrada R, Requena C, Llombart B, et al.
Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases. Actas Dermosifiliogr. 2008;99:281-90.

5. Stone R, Fliedner MC, Smiet AC. Management of oral mucositis in patients with cancer. Eur J Oncol Nurs. 2005;9:S24-32.

6. Hejna M, Köstler WJ, Raderer M, Steger GG, Brodowicz T, Scheithauer W, et al.
Decrease of duration and symptoms in chemotherapyinduced oral mucositis by topical GM-CSF: results of a prospective randomised trial. Eur J Cancer. 2001;37:1994-2002.

7. Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008;52:61-77, viii.
PMid:18154865    PMCid:2266835

8. López-Castaño F, Oñate-Sánchez RE, Roldán-Chicano R, Cabrerizo-Merino MC. Measurement of secondary mucositis to oncohematologic treatment by means of different scale. Review. Med Oral Patol Oral Cir Bucal. 2005; 10: 412-21.

9. Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, et al. The role of pro-inflammatory cytokines in cancer treatmentinduced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007;33:448-60.

10. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39:91-100.

11. Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 2010;46:452-6.

12. Napeñas JJ, Brennan MT, Bahrani-Mougeot FK, Fox PC, Lockhart PB. Relationship between mucositis and changes in oral microflora during cancer chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:48-59.

13. Antunes HS, Ferreira EM, Matos VD, Pinheiro CT, Ferreira CG. The Impact of low power laser in the treatment of conditioning-induced oral mucositis: A report of 11 clinical cases and their review. Med Oral Patol Oral Cir Bucal. 2008; 13: E189 -92.

14. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis. 2003;3:405-12.

15. Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2004;(1):CD001972.

16. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109: 820-31.

17. Colella G, Cannavale R, Vicidomini A, Rinaldi G, Compilato D, Campisi G. Efficacy of a spray compound containing a pool of collagen precursor synthetic aminoacids (l-proline, l-leucine, l-lysine and glycine) combined with sodium hyaluronate to manage chemo/ radiotherapy-induced oral mucositis: preliminary data of an open trial. Int J Immunopathol Pharmacol. 2010;23:143-51.

18. Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brünner N, Nauntofte B. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:217-26.

19. Hong CH, Napeñas JJ, Hodgson BD, Stokman MA, Mathers-Stauffer V, Elting LS, et al. A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer. 2010 May 7.

20. Raber-Durlacher JE, Epstein JB, Raber J, van Dissel JT, van Winkelhoff AJ, Guiot HF, et al. Periodontal infection in cancer patients treated with high-dose chemotherapy. Support Care Cancer. 2002;10:466-73.

21. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:39-44.

22. Minicucci EM, Lopes LF, Crocci AJ. Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia. Leuk Res. 2003;27:45-50.

23. Bagán JV, Diz-Dios P, Gallego L, Infante-Cossío P, Jiménez Y, Junquera LM, y cols. Recomendaciones para la prevención de la osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos intravenosos. Med Oral Patol Oral Cir Bucal. 2008;13:161-7.

24. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-7.

25. McLeod NM, Davies BJ, Brennan PA. Bisphosphonate osteonecrosis of the jaws; an increasing problem for the dental practitioner. Br Dent J. 2007;203:641-4.

26. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857-69.

27. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009;45:551-4.

28. Jimenez-Soriano Y, Bagan JV. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: An update. Med Oral Patol Oral Cir Bucal. 2005;10:E88-91.

29. Bagan JV, Jiménez Y, Hernández S, Murillo J, Díaz JM, Poveda R, et al. Osteonecrosis of the jaws by intravenous bisphosphonates and osteorradionecrosis: a comparative study. Med Oral. 2009; 14: e616-9.

30. Bagan JV, Jimenez Y, Diaz JM, Murillo J, Sanchis JM, Poveda R, et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: Proposal for a modification of the clinical classification. Oral Oncol. 2009;45:645-6.

31. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.J Oral Maxillofac Surg. 2005;63:1567-75.

32. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res. 2007;86:1013-21.

33. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122:S33-45.

34. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-410.

35. Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S. Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Dis. 2009;15:527-37.

36. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients- -May 2006. Crit Rev Oncol Hematol. 2007;62:148-52.

37. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117-20.

38. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20:137-45.

39. Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol. 2007;18:vi168-72.

40. Flichy-Fernández AJ, Balaguer-Martínez J, Peñarrocha-Diago M, Bagán JV. Bisphosphonates and dental implants: current problems. Med Oral Patol Oral Cir Bucal. 2009;14:E355-60.

41. Zahrowski JJ. Bisphosphonate treatment: an orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop. 2007;131:311-20.